Abstract
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease comprising multiple genetic subtypes that translates and impacts clinical outcomes after standard chemoimmunotherapy. Our initial understanding of the complex biological subtypes of DLBCL began with the identification of cell of origin (COO), and now has evolved to include even more specific subtypes defined by genetic signatures and mutations. These newer classifications lend themselves to the application of precision-based medicine, allowing us to tailor new treatment platforms that target specific oncogenic drivers in order to improve DLBCL outcomes. Essential to this is the development of genetic assays and tools that are reliable and readily available to assist in the application of these molecular classifications to real-world use. In this review, we discuss the history of DLBCL classification systems and their implication on clinical investigation as well as novel therapeutic options in DLBCL.
| Original language | English (US) |
|---|---|
| Article number | 4692 |
| Journal | Journal of Cancer Metastasis and Treatment |
| Volume | 8 |
| DOIs | |
| State | Published - 2022 |
Keywords
- DLBCL
- activated-B-cell
- germinal center
- molecular targets
- tumor heterogeneity
ASJC Scopus subject areas
- Oncology